F84.9 Insurance Policy Changes

ICD-10 F84.9 is officially defined as "Pervasive developmental disorder, unspecified." code F84.9 is referenced in 15 tracked payer policy changes from Independence Blue Cross, Wisconsin Medicaid (ForwardHealth), and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code F84.9 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Independence Blue Cross · Effective Oct 19, 2026Medium impact
14.00.03c, Applied Behavior Analysis (ABA) for the Treatment of Autism Spectrum Disorder (ASD)
Independence Blue Cross updated medical policy 14.00.03c on Applied Behavior Analysis (ABA) for autism spectrum disorder treatment, effective 10/19/2026. Changes include improved policy organization and clarity, updated reassessment intervals (every 6 months), and expanded language regarding convenience-based care to explicitly include child, member, parent(s), guardian(s), or caregiver(s). Coverage criteria for ABA remain contingent on documented ASD diagnosis, validated assessment tools, and functional behavior assessment by qualified professionals.
Wisconsin Medicaid (ForwardHealth) · Effective Oct 1, 2026Medium impact
ForwardHealth Covers Dental Case Management for Members With Special Health Care Needs
Beginning October 1, 2026, ForwardHealth covers dental case management for members with special health care needs, reimbursed under CDT code D9997 at $100 per visit. Prior authorization is required for more than one visit per member within 180 days, for D9997 billed with moderate to deep dental sedation in that period, for a member whose diagnosis is not a qualifying code but has documented medical necessity, and when the place of service is 15 (Mobile Unit). Prior authorization is not required for the first visit per member, per provider, every six months (180 days).
Independence Blue Cross · Effective Dec 31, 2025Medium impact
14.00.03b, Applied Behavior Analysis (ABA) for the Treatment of Autism Spectrum Disorder (ASD)
Independence Blue Cross expanded ABA coverage criteria to recognize board certified behavior analysts (BCBA) and licensed behavior specialists (LBS) as qualified providers, and broadened the definition of supervising professionals to include qualified health professionals (QHP) beyond just MD/DO/psychologists. The policy remains effective 12/31/2025 with updated medically necessary criteria for ABA treatment of autism spectrum disorder.
Aetna · Identified Oct 28, 2026Medium impact
Applied Behavior Analysis (CPB 0554, reviewed 2026-10-14)
Aetna's Clinical Policy Bulletin 0554 on applied behavior analysis (ABA) says Aetna considers ABA experimental, investigational or unproven for Down syndrome in the absence of an autism spectrum disorder (ASD) co-morbidity and for all other non-ASD indications. CPT codes 97151 through 97158 are not covered for the indications listed in the policy. ICD-10 codes F84.0 through F84.9 are covered if selection criteria are met, and ICD-10 codes Q90.0 through Q90.9 (Down syndrome) are not covered for the indications listed.
Aetna · Identified Oct 23, 2026Medium impact
Autism Spectrum Disorders (CPB 0648, reviewed 2026-10-20)
Aetna considers autism spectrum disorder (ASD) evaluation and diagnosis medically necessary when developmental delays or persistent deficits in social communication and social interaction across multiple contexts have been identified and the evaluation is performed by an appropriate certified or licensed health care professional. The following services may be included in the assessment and treatment of ASD: ASD-specific developmental evaluation, cognitive and adaptive behavior evaluations, speech-language evaluation, formal audiological hearing evaluation, genetic testing within stated criteria, medical evaluation, and pharmacotherapy for co-morbidities subject to the member's drug benefits. The policy lists many assessments and treatments as experimental, investigational, or unproven, including the EarliPoint eye-tracking test, metabolomic blood tests, chelation therapy, and hyperbaric oxygen therapy, and it states that services primarily educational in nature are not covered under medical benefits.
Aetna · Identified Oct 4, 2026Medium impact
Hematopoietic Cell Transplantation for Autoimmune Diseases and Miscellaneous Indications (CPB 0606, reviewed 2026-09-18)
Aetna considers autologous hematopoietic cell transplantation medically necessary for adults 18 to 69 years old with rapidly progressive scleroderma (systemic sclerosis) at risk of organ failure. This applies when active interstitial lung disease is present with a forced vital capacity or diffusing capacity of the lung for carbon monoxide below 70% of predicted, or when previous scleroderma-related renal disease is present, and the member meets the transplanting institution's selection criteria or, if there are none, has none of the listed exclusion criteria. Aetna considers autologous or allogeneic hematopoietic cell transplantation experimental, investigational, or unproven for conditions including multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, myasthenia gravis, type I diabetes mellitus, age-related macular degeneration, amyotrophic lateral sclerosis, polycythemia vera, and thrombotic thrombocytopenic purpura.
Aetna · Identified Oct 4, 2026Medium impact
Suit Therapy (CPB 0696, reviewed 2026-09-18)
Suit therapy, including the Adeli Suit, TheraTogs and other suit therapy devices, is considered experimental, investigational or unproven for cerebral palsy and other conditions, including gait rehabilitation following stroke. Dynamic movement orthoses are considered experimental, investigational or unproven for cerebral palsy, hemiparesis or hemiplegia, scoliosis and all other indications. The Dynamic Lycra Suit TLSO brace is considered experimental for cerebral palsy or scoliosis, and a TLSO is considered experimental for autism. The Benik vest or trunk support is considered experimental for individuals with low trunk tone and all other indications.
Aetna · Identified Aug 18, 2026Medium impact
Hospitalization for the Initiation of Ketogenic Diet (CPB 0226, reviewed 2026-04-23)
Aetna considers hospitalization for initiation of a ketogenic diet medically necessary for intractable seizures, including Doose syndrome and Lennox-Gastaut syndrome, when all listed selection criteria are met, and for persons with glucose transporter protein type 1 deficiency or pyruvate dehydrogenase complex deficiency. Aetna considers hospitalization for initiation of a ketogenic diet of unproven value for all other indications, including adult super-refractory status epilepticus, Alzheimer's disease, autism spectrum disorder, cancer, migraine prevention, multiple sclerosis, Parkinson's disease, schizophrenia and type 2 diabetes. Hospitalization for initiation of the Atkins diet for intractable seizures, mitochondrial diseases, or other indications is considered experimental, investigational, or unproven.
Aetna · Identified Aug 17, 2026Medium impact
Applied Behavior Analysis (CPB 0554, reviewed 2025-11-26)
Aetna considers applied behavior analysis (ABA) experimental, investigational, or unproven for Down syndrome in the absence of an autism spectrum disorder (ASD) comorbidity and for all other non-ASD indications. CPT 97151 through 97158 (adaptive behavior assessment and treatment) are not covered for the indications listed. ABA for autism is covered for ICD-10 codes F84.0 through F84.9 when selection criteria are met, and Down syndrome codes Q90.0 through Q90.9 are not covered for the indications listed.
Aetna · Identified Aug 17, 2026Medium impact
Hematopoietic Cell Transplantation for Autoimmune Diseases and Miscellaneous Indications (CPB 0606, reviewed 2025-09-10)
Aetna's Clinical Policy Bulletin 0606 covers hematopoietic cell transplantation for autoimmune diseases and other listed conditions. Aetna considers autologous transplant medically necessary for adults aged 18 to 69 with rapidly progressive scleroderma (systemic sclerosis) at risk of organ failure when either active interstitial lung disease with an FVC or DLCO below 70% of predicted is present, or previous scleroderma-related renal disease is present, and the member meets the transplanting institution's selection criteria or, where none exist, has none of the listed exclusion criteria. Aetna considers autologous or allogeneic transplant experimental, investigational or unproven for many autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, type 1 diabetes and myasthenia gravis, and for miscellaneous conditions such as age-related macular degeneration, amyotrophic lateral sclerosis, polycythemia vera and thrombotic thrombocytopenic purpura.
Aetna · Identified Aug 17, 2026Medium impact
Suit Therapy (CPB 0696, reviewed 2025-11-26)
Aetna considers suit therapy, including home use of suit therapy devices such as the Adeli Suit and TheraTogs, experimental, investigational, or unproven for members with cerebral palsy or other conditions, such as gait rehabilitation following stroke. Aetna also considers dynamic movement TLSO braces (Dynamic Lycra Suits) for cerebral palsy or scoliosis, Dynamic Movement Orthoses for cerebral palsy, hemiparesis or hemiplegia, scoliosis and all other indications, TLSO braces for autism, and the Benik vest for low trunk tone and all other indications experimental, investigational, or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Fecal Bacteriotherapy (CPB 0844, reviewed 2026-03-25)
Aetna's commercial clinical policy bulletin 0844 covers fecal bacteriotherapy. It considers fecal microbiota transplant medically necessary for Clostridium difficile infection (CDI) confirmed by a positive C. difficile toxin stool test that has recurred after at least one course of adequate antibiotic therapy. It considers a single rectal dose of Rebyota (fecal microbiota, live-jslm) medically necessary for preventing CDI when the policy's criteria are met, and it considers other listed indications, including alcoholic hepatitis, Crohn's disease, ulcerative colitis and irritable bowel syndrome, experimental, investigational, or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Celiac Disease Laboratory Testing (CPB 0561, reviewed 2026-08-03)
Serological testing for IgA anti-human tissue transglutaminase (TTG), IgG and IgA deamidated gliadin (DGP), and IgA anti-endomysial (EMA) antibodies is medically necessary as a preliminary diagnostic test for persons with symptoms suggestive of celiac disease, to monitor response to a gluten-free diet, to screen first-degree relatives of individuals with celiac disease, and to screen persons with type 1 diabetes. HLA-DQ2 and HLA-DQ8 genetic testing is medically necessary for listed situations, including seronegative persons with equivocal small bowel histology findings (Marsh I-II), evaluation of persons on a gluten-free diet in whom no serologic testing was performed before starting it, and persons with Down syndrome. Anti-gliadin antibody (AGA) and anti-reticulin antibody (ARA) testing, the Prometheus Celiac Plus Panel, and HLA genotyping for screening persons with type 1 diabetes are experimental, investigational, or unproven.
Aetna · Identified Aug 14, 2026Medium impact
Sensory and Auditory Integration Therapy (CPB 0256, reviewed 2026-04-15)
Aetna considers sensory integration therapy and auditory integration therapy (also known as auditory integration training) experimental, investigational, or unproven for the management of persons with various communication, behavioral, emotional, and learning disorders and for all other indications. The effectiveness of these therapies is unproven. CPT code 97533 is not covered for the indications listed in this policy, and the listed ICD-10 codes are not covered for those indications either.
Aetna · Identified Aug 12, 2026Medium impact
Autism Spectrum Disorders (CPB 0648, reviewed 2025-10-02)
Aetna Clinical Policy Bulletin 0648 covers evaluation and treatment of autism spectrum disorder (ASD). ASD evaluation and diagnosis is considered medically necessary when developmental delays or persistent deficits in social communication and social interaction across multiple contexts have been identified and the evaluation is performed by an appropriate certified or licensed health care professional. The services that may be included in assessment and treatment are ASD-specific developmental evaluation, cognitive and adaptive behavior evaluations, speech and language evaluation by a speech-language pathologist, formal audiological hearing evaluation, medical evaluation, and selected genetic and metabolic testing when criteria are met. Intensive educational interventions, pharmacotherapy for co-morbidities, behavior modification for behavioral co-morbidities, and physical and occupational therapy for co-morbid physical impairments may also be included. The policy lists numerous tests and treatments as experimental, investigational, or unproven for ASD.

Watch F84.9

Get one email when a payer policy names F84.9, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code F84.9?

There are 15 tracked policy changes affecting code F84.9, including updates from Independence Blue Cross, Wisconsin Medicaid (ForwardHealth), Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code F84.9?

Payers that have issued tracked updates for code F84.9 include: Independence Blue Cross, Wisconsin Medicaid (ForwardHealth), Aetna.

How do I get notified when code F84.9 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code F84.9. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code F84.9?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

14.00.03c, Applied Behavior Analysis (ABA) for the Treatment of Autism Spectrum Disorder (ASD)

ForwardHealth Covers Dental Case Management for Members With Special Health Care Needs

14.00.03b, Applied Behavior Analysis (ABA) for the Treatment of Autism Spectrum Disorder (ASD)

Applied Behavior Analysis (CPB 0554, reviewed 2026-10-14)

Autism Spectrum Disorders (CPB 0648, reviewed 2026-10-20)

Hematopoietic Cell Transplantation for Autoimmune Diseases and Miscellaneous Indications (CPB 0606, reviewed 2026-09-18)

Suit Therapy (CPB 0696, reviewed 2026-09-18)

Hospitalization for the Initiation of Ketogenic Diet (CPB 0226, reviewed 2026-04-23)

Applied Behavior Analysis (CPB 0554, reviewed 2025-11-26)

Hematopoietic Cell Transplantation for Autoimmune Diseases and Miscellaneous Indications (CPB 0606, reviewed 2025-09-10)

Suit Therapy (CPB 0696, reviewed 2025-11-26)

Fecal Bacteriotherapy (CPB 0844, reviewed 2026-03-25)

Celiac Disease Laboratory Testing (CPB 0561, reviewed 2026-08-03)

Sensory and Auditory Integration Therapy (CPB 0256, reviewed 2026-04-15)

Autism Spectrum Disorders (CPB 0648, reviewed 2025-10-02)

What insurance policy changes affect code F84.9?

Which payers have updated policy for code F84.9?

How do I get notified when code F84.9 policy changes?

Why do payers change policies for code F84.9?